Uche Mordi

Uche Mordi

Auto-generated profile, based on publicly available information

Uche Mordi

Gilead Sciences, Inc., Foster City, CA 94404, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
PSPatrick S. Sullivan
Patrick S. Sullivan
CCCillian Copeland
Cillian Copeland
JJJames Jarrett
James Jarrett
UMUche Mordi
Uche Mordi
NKNikos Kotsopoulos
Nikos Kotsopoulos
HTHansel E. Tookes
Hansel E. Tookes
Introduction International guidelines emphasize the need for earlier commencement of antiretroviral therapy (ART) among people with HIV (PWH). Reducing the time between HIV diagnosis and ART initiation can improve health outcomes, reduce healthcare utilization, and reduce HIV transmissions. This study evaluated the clinical and economic benefits associated with increasing uptake of rapid start ART among newly diagnosed PWH. Methods A state transition disease model was developed in the United States setting to evaluate the benefits from earlier initiation of ART. The base case analysis compared two cohorts of 1000 newly diagnosed PWH: one following current patterns of ART initiation, and a counterfactual cohort where those receiving rapid start ART was doubled. Individuals were classified by different CD4 states at diagnosis and over time with viral suppression rates also being tracked. ART and CD4 state-specific healthcare costs were estimated over a 3-year time horizon. Averted HIV transmissions were calculated and used to estimate lifetime healthcare cost savings while CD4-specific mortality was also calculated. Several scenario analyses explored alternate assumptions related to the time at which PWH started ART after diagnosis. Results Doubling the proportion of newly diagnosed PWH receiving rapid start ART averted 7 HIV transmissions and 0.3 deaths per 1000 people, corresponding to numbers needed to treat of 141 and 3502, respectively. This leads to cost savings resulting from reduced healthcare resource use and lifetime cost savings from preventing new HIV transmissions. Conclusion Reducing the time between HIV diagnosis and ART initiation can provide clinical and economic benefits by eliminating transmissions that might occur while individuals are viremic but not on treatment. The additional costs of providing ART required for this increase achieve high levels of return when considering the lifetime healthcare cost burden of onward HIV transmissions potentially averted by early ART start.

1 October 2025 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
CCCillian Copeland
Cillian Copeland
RMRui Martins
Rui Martins
RTRyan Thaliffdeen
Ryan Thaliffdeen
NKNikos Kotsopoulos
Nikos Kotsopoulos
JJJames Jarrett
James Jarrett
MPMaarten J. Postma
Maarten J. Postma
Background: The United States (US) HIV/AIDS strategy has targeted a 90% reduction in HIV infections by 2030. Whilst progress has been made in US HIV policy, the persistence of nearly 32,000 new infections annually highlights substantial barriers that still hinder effective treatment and the achievement of national targets. While the humanistic burden of HIV is well documented, there are broader economic effects on employment, disability and retirement. The objective of this study is to evaluate these economic gains when improving various HIV policies. Methodology: This analysis adapts a published Markov model assessing the role of six key policy parameters related to diagnosis, pre-exposure prophylaxis (PrEP) uptake, treatment initiation, and treatment as prevention (TasP) on the HIV epidemic in the US. Improvements in these parameters were explored to estimate averted HIV infections over 50 years and, subsequently, the feasibility of achieving the 2030 target of a 90% reduction in HIV incidence. A fiscal economic framework was also applied, linking HIV cases and policy targets to productivity, tax revenue, transfer benefits, and healthcare costs incurred by the US government. Results: Results were calculated for the general US population and for men who have sex with men (MSM), a subgroup experiencing a high HIV burden. For the general US population, policy improvements led to an average of 5,324 averted HIV infections annually over the 50-year horizon, corresponding to a total net annual fiscal gain of $397 million or $74,511 per averted infection. For the MSM subgroup, 911 infections were averted annually resulting in a net fiscal gain of $96 million, or $105,031 per averted infection. Conclusion: This analysis demonstrates that the benefits of HIV policy are not limited to the healthcare setting and show how initial investments provide long-term benefits by preventing HIV transmission and the associated impact on individuals’ labor market outcomes. While relying on assumptions and projections that may not capture all real-word complexities, fiscal analyses can provide a useful tool for policy evaluation that facilitate a holistic assessment of the wider costs and benefits that fall on governments as well as benefits of achieving policy targets.

9 June 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Closed access
SSScott Sutton
Scott Sutton
JMJoseph Magagnoli
Joseph Magagnoli
TCTammy H. Cummings
Tammy H. Cummings
CWChase Williams
Chase Williams
MCMary J Christoph
Mary J Christoph
PTPhyllis C Tien
Phyllis C Tien
Background: This study evaluated clinical and economic outcomes associated with antiretroviral therapy (ART) resistance among people with HIV (PWH) within a nationally representative database. Methods: Retrospective claims data were extracted from the Veterans Affairs Informatics and Computing Infrastructure. PWH receiving testing for resistance-associated mutations (RAMs) between 2003 and 2023 were categorized as resistant if they had ≥1 documented RAM in integrase strand transfer inhibitor, protease inhibitor, or reverse transcriptase genes. Results: Among 7746 veterans with interpretable resistance tests, 1875 had no detectable resistance, 4466 had ≥1 major or minor RAM (any RAM), and 1405 had ≥1 major RAM. The median CD4 count was highest for those without RAMs (357 cells/mm3) and lowest for those with major RAMs (285 cells/mm3). Opportunistic infections during the 1-year follow-up were present in 3.8% without RAMs as compared with >5% for both RAM groups. Hospitalizations were more frequent in the major RAM and any RAM cohorts vs the no resistance cohort (P < .001 for both). Total all-cause costs averaged $45 476 for those without RAMs as compared with $49 945 for those with any RAM and $48 392 for those with a major RAM. Among PWH initiating ART after resistance testing (n = 3522), those without RAMs had the longest persistence, while those with RAMs had shorter persistence (P < .0001). PWH prescribed ART at the time of resistance testing who had RAMs were most likely to switch to a regimen based on an integrase strand transfer inhibitor or protease inhibitor. Conclusions: In this real-world analysis, PWH with detectable resistance had lower CD4 counts, more frequent hospitalizations and opportunistic infections, greater economic costs, and increased discontinuation of ART.

1 May 2026 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
UMUche Mordi
Uche Mordi
MCMary J Christoph
Mary J Christoph
BCBenjamin Chastek
Benjamin Chastek
TLTravis Lim
Travis Lim
NMNeia Prata Menezes
Neia Prata Menezes
JCJoshua Cohen
Joshua Cohen
Aim: There are limited studies of antiretroviral therapy persistence among people with HIV (PWH) who have a mental health disorder and/or substance use disorder (MHD/SUD). This real-world study analyzed persistence among treatment-experienced PWH who had an MHD/SUD or suboptimal adherence (proportion of days covered [PDC] < 85%). Materials & methods: In this retrospective cohort study of claims from the Optum Research Database, nonpersistence (i.e., discontinuation, switch, add-on or death) was assessed in treatment-experienced PWH who switched to or restarted an antiretroviral therapy regimen of interest (i.e., bictegravir [B]/emtricitabine [F]/tenofovir alafenamide [TAF], dolutegravir [DTG]/lamivudine [3TC], DTG/abacavir [ABC]/3TC, DTG + F/TAF, DTG + F/tenofovir disoproxil fumarate [TDF] or cabotegravir + rilpivirine) from 1 July 2017 to 30 November 2023. Baseline characteristics across regimens were balanced by inverse probability treatment weighting. Kaplan–Meier analysis was conducted on weighted data to examine regimen persistence at 12 months. Adjusted Cox proportional hazards models assessed nonpersistence throughout follow-up. Results: Overall, 14,826 PWH were eligible and treatment experienced; 5310 had an MHD/SUD and 4090 had PDC < 85% during follow-up. Among treatment-experienced PWH who received B/F/TAF, persistence at 12 months was 80.3% for those with an MHD/SUD and 78.6% for those with PDC < 85%; this was greater compared with PWH who received DTG/3TC (76.7% and 70.8%), DTG/ABC/3TC (68.9% and 66.3%), DTG + F/TAF (62.4% and 58.9%) and DTG + F/TDF (36.7% and 41.9%; all p < 0.05). Compared with B/F/TAF, nonpersistence risk was greater with DTG/3TC, DTG/ABC/3TC, DTG + F/TAF and DTG + F/TDF in the MHD/SUD (all p < 0.05) and PDC < 85% (all p < 0.05 except DTG/3TC) groups. Conclusion: These results indicate that B/F/TAF may offer greater likelihood of persistence and emphasize the importance of regimen selection to optimize outcomes in treatment-experienced PWH with an MHD/SUD or suboptimal adherence.

21 September 2026 in Journal of Medical Economics
Verified
Journal Article
Open access
JCJoshua Cohen
Joshua Cohen
MCMary J. Christoph
Mary J. Christoph
VAVamshi Ruthwik Anupindi
Vamshi Ruthwik Anupindi
NSNazneen Fatima Shaikh
Nazneen Fatima Shaikh
JCJeanPierre Coaquira
JeanPierre Coaquira
ANAimee M. Near
Aimee M. Near
Human immunodeficiency virus (HIV) remains a substantial public health challenge in the United States (US). As of 2023, an estimated 1.13 million people aged 13 years or older were living with HIV ...

26 March 2026 in Journal of Health Economics and Outcomes Research
Verified
Journal Article
Open access
PDF file
HTHansel E. Tookes
Hansel E. Tookes
CCCillian Copeland
Cillian Copeland
UMUche Mordi
Uche Mordi
JJJames Jarrett
James Jarrett
RMRui Martins
Rui Martins
PSPatrick S. Sullivan
Patrick S. Sullivan
Background: Antiretroviral therapy (ART) has become a cornerstone of human immunodeficiency virus (HIV) management. However, a challenge in HIV care and policy is ensuring individuals remain engaged in care and on treatment over time. Discontinuation of ART is common for various reasons, and prolonged treatment interruptions can lead to worse health outcomes at the individual level and increased HIV transmissions at the public health level. Objective: A cost-consequence analysis was conducted to evaluate the economic and public health impact of reducing the interval to ART restart among people with HIV (PWH) who have disengaged from care. Methods: A state transition disease model was developed to calculate the economic benefits from improving treatment restart patterns from a United States healthcare payer perspective. Two hypothetical cohorts of 1000 PWH who discontinued ART were compared: a standard-of-care cohort where restart occurs 32 weeks after discontinuation, and a comparator cohort exploring the impact of reducing the time between ART discontinuation and restart to 12 weeks. Individuals were assigned to CD4-related health states, and rates of viral suppression were considered. Four outcomes, ART costs, CD4 health state costs, CD4-related mortality, and new HIV transmissions were calculated over a three-year time horizon. Cost savings from averted HIV cases were valued based on the lifetime excess healthcare costs for a PWH. Results: Increasing the proportion of individuals restarting ART and reducing time to restart was estimated to avert 88 HIV transmissions. This corresponds to a number needed to treat, defined as the number of PWH who would need to experience the earlier restart pattern of the comparator cohort, of 11 to avoid one new transmission, and $101 083 857 lifetime cost savings. Cost savings attributable to improved CD4 counts in the cohort were also found. Conclusion: Enhancing ART restart patterns improves health and provides considerable cost savings by improving individuals’ CD4 counts and reducing new HIV transmissions from people who are viremic. Effective policies to promote care engagement and treatment adherence are predicted to improve the health of PWH and reduce new HIV cases.